Madrigal Pharmaceuticals, Inc. (MDGL) Stock Price, Quote, News & Analysis

MDGL Madrigal Pharmaceuticals, Inc.
Stock Price & Overview

$229.58-5.27 (-2.24%)4:00 PM 05/24/24
NASDAQ | $USD | Market Close

Charts

52 Week Range
119.76
299.98
Day Range
229.58
229.58
EPS (FWD)
-28.62
PE
-
Div Rate
-
Yield
-
Market Cap
$4.89B
Volume
374,487
Prev. Close
$234.85
Expand For Key Data »

Quant Ranking

MDGL Analysis

See All Analysis »

MDGL News

See All News »

Latest Headlines

Ratings Summary

People Also Follow

Compare

Similar to MDGL

SymbolLast PriceChange
APLS
0
0.00%
Apellis Pharmaceuticals, Inc.
CRSP
0
0.00%
CRISPR Therapeutics AG
KRYS
0
0.00%
Krystal Biotech, Inc.
BBIO
0
0.00%
BridgeBio Pharma, Inc.
IBRX
0
0.00%
ImmunityBio, Inc.
Compare

ETFs Holding MDGL

MDGL Company Profile

Madrigal Pharmaceuticals, Inc. logo
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
Sector
Health Care
Industry
Biotechnology
Employees
376
Founded
-
Address
  • Four Tower Bridge
  • Suite 200
  • 200 Barr Harbor Drive
  • West Conshohocken, PA, 19428
  • United States
Phone Number
267 824 2827
Website
www.madrigalpharma.com
Hide

MDGL Revenue

More On Revenue »

MDGL Earnings Per Share

More On Earnings »

Earnings Estimates

FY
EPS
YoY
PE
Sales
YoY
2024
-28.62
-43.16%
-8.02
$75.76M
-
2025
-17.98
+37.19%
-12.77
$361.09M
+376.65%
2026
3.46
NM
66.28
$959.35M
+165.68%
More On Earnings Estimates »

Earnings Revisions

Rating:
FY1 Up Revisions
0
FY1 Down Revisions
11
100% Down0% Up
More On Earnings Revisions »

Valuation

Rating:
P/E Non-GAAP (FWD)
NM
P/E GAAP (TTM)
NM
Price/Book (TTM)
5.58
EV/Sales (TTM)
-
EV/EBITDA (TTM)
NM
More On Valuation »

Profitability

Rating:
Gross Profit Margin
-
EBIT Margin
-
Net Income Margin
-
Return on Equity
-88.78%
Return on Assets
-41.05%
More On Profitability »

Momentum

Rating:
Ticker
3M
6M
9M
1Y
MDGL
-2.94%
+17.40%
+29.51%
-21.45%
SP500
+4.24%
+16.35%
+21.21%
+28.90%

52 Week Range

119.76
Last price: 229.58
299.98
More On Momentum »

Capital Structure

Market Cap
$4.89B
Total Debt
$117.72M
Cash
$1.06B
Other
-
Enterprise Value
$3.95B

Trading Data

Volume
374,487
Average Volume (3 months)
487,490
Previous Close
234.85
Open
234.81
Shares Outstanding (Ticker)
21.31M

Dividends

MDGL does not currently pay a dividend.

MDGL Ownership

Type
Common Stock Held
% of Shares Outstanding
Market Value
Composition
Institutions
15.42M
63.08%
3.54B
Corporations (Private)
837,671
3.43%
192.31M
Individuals / Insiders
2.50M
10.21%
572.98M
Hedge Fund Managers
5.69M
23.28%
1.31B
Total
24.44M
100.00%
5.61B

MDGL Peers

Title
APLSCRSPKRYSBBIO
Company name
Apellis Pharmaceuticals, Inc.
CRISPR Therapeutics AG
Krystal Biotech, Inc.
BridgeBio Pharma, Inc.
Industry
BiotechnologyBiotechnologyBiotechnologyBiotechnology
Market Cap
4.93B
4.69B
4.65B
5.23B
Employees
704
407
229
553

Go Premium to see ratings on MDGL peers.

More On Peers »

Risk

24M Beta
0.86
Altman Z Score
-

Technicals

Title
10D SMA
50D SMA
200D SMA
Simple Moving Average
224.53
231.78
203.10
Last Price vs SMA
+2.25%
-0.95%
+13.04%
More On Moving Averages »

MDGL Transcripts

See All Transcripts »

Investor Presentations

MDGL SEC Filings

See All SEC Filings »

Press Releases

See All Press Releases »

MDGL Income Statement

Revenue (TTM)
-
Revenue Per Share
-
Gross Profit (TTM)
-
EBITDA (TTM)
-453.63M
Net Income (TTM)
-444.28M
EPS Diluted (TTM)
-$23.21
Full Income Statement »

MDGL Balance Sheet

Total Cash (MRQ)
1.06B
Total Cash Per Share
30.10
Total Debt (MRQ)
117.72M
Total Debt to Equity (MRQ)
13.84%
Current Ratio (MRQ)
9.39
Quick Ratio (MRQ)
9.26
Full Balance Sheet »

MDGL Cash Flow Statement

Cash from Operations (TTM)
-389.32M
Cash from Investing (TTM)
-217.60M
Levered Free Cash Flow (TTM)
-229.94M
Unlevered Free Cash Flow (TTM)
-223.69M
Free Cash Flow / Share (TTM)
-$20.43
Full Cash Flow Statement »

MDGL Long Term Solvency

Total Debt / Equity (MRQ)
13.84
Total Debt / Capital (MRQ)
12.16
LT Debt / Equity (MRQ)
13.77
LT Debt / Total Capital (MRQ)
12.10
Total Liabilities / Total Assets (MRQ)
21.39

Discover More

You may be interested in:

Madrigal Pharmaceuticals, Inc. (MDGL) Frequently Asked Questions

  • 14 analysts have issued ratings. Wall Street analysts rate MDGL as Bullish on average, for a Wall Street consensus of buy. View MDGL’s ratings here. 4 Seeking Alpha authors also rated the stock, and their ratings often outperform those of Wall Street analysts. Here are their ratings on MDGL

  • Madrigal Pharmaceuticals, Inc. is currently listed on NASDAQ under MDGL. One share of MDGL stock can currently be purchased for approximately $229.58.

  • Madrigal Pharmaceuticals, Inc. is listed on the NASDAQ as (NASDAQ:MDGL).

  • Madrigal Pharmaceuticals, Inc.'s stock symbol is MDGL and currently trades under NASDAQ. It’s current price per share is approximately $229.58.

  • 14 Wall Street analysts have issued ratings. Currently, 11 analysts rated MDGL as Bullish, 1 rated it Bearish, and 2 rated it Neutral. This suggests a possible increase. View MDGL’s analyst predictions. 4 Seeking Alpha authors also rated the stock, and their ratings often outperform those of Wall Street analysts. Here are their ratings on MDGL

  • 14 Wall Street analysts currently have issued price targets for MDGL. On average, MDGL’s share price is expected to reach $363.86. This means MDGL may see an increase. Read more about ratings here.

  • Madrigal Pharmaceuticals, Inc.’s latest quarterly earnings per share is $-7.38 with a past EPS surprise of $-0.99. The latest EPS estimate is $-7.78. Read more about Madrigal Pharmaceuticals, Inc.’s earnings.

  • Madrigal Pharmaceuticals, Inc. is currently listed on the NASDAQ under MDGL. You can buy Madrigal Pharmaceuticals, Inc. stock in the US through any online brokerage account such as E*TRADE, Charles Schwab, or Merrill Edge. Premium subscribers can easily link their Seeking Alpha portfolios to their brokerage account. (Your credentials will never be made accessible to Seeking Alpha.)

  • Madrigal Pharmaceuticals, Inc.’s mailing address is Four Tower Bridge, West Conshohocken PA 19428, United States. They can be reached by phone at 267 824 2827.

  • Shareholders of MDGL might also be interested in these stocks: APLS, CRSP, KRYS, BBIO, IBRX. View more information about MDGL’s peers here.

People Also Follow

Compare

Similar to MDGL

SymbolLast PriceChange
APLS
0
0.00%
Apellis Pharmaceuticals, Inc.
CRSP
0
0.00%
CRISPR Therapeutics AG
KRYS
0
0.00%
Krystal Biotech, Inc.
BBIO
0
0.00%
BridgeBio Pharma, Inc.
IBRX
0
0.00%
ImmunityBio, Inc.
Compare

ETFs Holding MDGL